MELK-8a

• Description :

  MELK-8a (NVS-MELK8a) is a highly potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor with IC50 of 2 nM. MELK-8a also inhibits Flt3 (ITD), Haspin, PDGFRα with IC50s of 0.18, 0.19, and 0.42 μM, respectively. MELK plays an essential role in regulating cell mitosis in a subset of cancer cells[1].

• Product Name Alternative :

  NVS-MELK8a

• UNSPSC :

  12352005

• Target :

  Haspin Kinase; MELK; Mitosis; PDGFR

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/melk-8a.html

• Purity :

  98.32

• Solubility :

  DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  CN(CC1)CCN1C2=CC=C(N3C=C(C4=CC=NC=C4OCC5CCNCC5)C=N3)C=C2

• Molecular Formula :

  C25H32N6O

• Molecular Weight :

  432.56

• References & Citations :

  [1]B Barry Touré, et al. Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight. J Med Chem. 2016 May 26;59 (10) :4711-23.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1922153-17-0]